Atoltivimab

DB15898

biotech approved

Deskripsi

Ebola virus (EBOV) remains an important human pathogen within the Ebolavirus genus, having been responsible for at least 17 known outbreaks with an average case fatality rate of 43.92%.A221825 Immune therapy using monoclonal antibodies (mAbs) is becoming an increasingly attractive therapeutic method to combat infectious diseases due to its rapid development, low toxicity, and high specificity.A222078 The chief surface target of EBOV particles is the GP1,2 glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic (i.e. through Fc-mediated immune effector function) antibody effects to play a role in combatting EBOV infection.A221825, A221830 A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.A222078

INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1? mAbs Atoltivimab (REGN 3470), Odesivimab (REGN 3471), and Maftivimab (REGN 3479) in equimolar proportions. All three mAbs bind to a distinct portion of the GP1,2 glycoprotein and collectively provide neutralizing and Fc-mediated immune effector function against EBOV in vitro and protection against EBOV infection in vivo. INMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.L17320

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Atoltivimab administered to healthy subjects at 50 mg/kg has a mean elimination half-life of 21.2 ± 3.36 days.[L17320]
Volume Distribusi Atoltivimab administered to healthy subjects at 50 mg/kg produced a mean steady-state volume of distribution of 58.2 ± 2.66 mL/kg.[L17320]
Klirens (Clearance) Atoltivimab administered to healthy subjects at 50 mg/kg has a mean clearance of 3.08 ± 0.719 mL/day/kg.[L17320]

Absorpsi

Atoltivimab administered to healthy subjects at 50 mg/kg produced a mean Cmax of 1220 ± 101 mg/L and a mean AUC0-? of 17,100 ± 4480 mg\*day/L.L17320

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

386 Data
Diethylstilbestrol Diethylstilbestrol may increase the thrombogenic activities of Atoltivimab.
Chlorotrianisene Chlorotrianisene may increase the thrombogenic activities of Atoltivimab.
Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Atoltivimab.
Estrone Estrone may increase the thrombogenic activities of Atoltivimab.
Estradiol Estradiol may increase the thrombogenic activities of Atoltivimab.
Dienestrol Dienestrol may increase the thrombogenic activities of Atoltivimab.
Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Atoltivimab.
Mestranol Mestranol may increase the thrombogenic activities of Atoltivimab.
Estriol Estriol may increase the thrombogenic activities of Atoltivimab.
Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Atoltivimab.
Quinestrol Quinestrol may increase the thrombogenic activities of Atoltivimab.
Hexestrol Hexestrol may increase the thrombogenic activities of Atoltivimab.
Tibolone Tibolone may increase the thrombogenic activities of Atoltivimab.
Synthetic Conjugated Estrogens, A Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Atoltivimab.
Synthetic Conjugated Estrogens, B Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Atoltivimab.
Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Atoltivimab.
Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Atoltivimab.
Zeranol Zeranol may increase the thrombogenic activities of Atoltivimab.
Equol Equol may increase the thrombogenic activities of Atoltivimab.
Promestriene Promestriene may increase the thrombogenic activities of Atoltivimab.
Methallenestril Methallenestril may increase the thrombogenic activities of Atoltivimab.
Epimestrol Epimestrol may increase the thrombogenic activities of Atoltivimab.
Moxestrol Moxestrol may increase the thrombogenic activities of Atoltivimab.
Estradiol acetate Estradiol acetate may increase the thrombogenic activities of Atoltivimab.
Estradiol benzoate Estradiol benzoate may increase the thrombogenic activities of Atoltivimab.
Estradiol cypionate Estradiol cypionate may increase the thrombogenic activities of Atoltivimab.
Estradiol valerate Estradiol valerate may increase the thrombogenic activities of Atoltivimab.
Biochanin A Biochanin A may increase the thrombogenic activities of Atoltivimab.
Formononetin Formononetin may increase the thrombogenic activities of Atoltivimab.
Estetrol Estetrol may increase the thrombogenic activities of Atoltivimab.
Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Atoltivimab.
Human immunoglobulin G The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Atoltivimab.
Omalizumab The risk or severity of adverse effects can be increased when Omalizumab is combined with Atoltivimab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Atoltivimab.
Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Atoltivimab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Atoltivimab.
Indium In-111 satumomab pendetide The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Atoltivimab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Atoltivimab.
Trastuzumab The risk or severity of adverse effects can be increased when Trastuzumab is combined with Atoltivimab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Atoltivimab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Atoltivimab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Atoltivimab.
Digoxin Immune Fab (Ovine) The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Atoltivimab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Atoltivimab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Atoltivimab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Atoltivimab.
Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Atoltivimab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Atoltivimab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Atoltivimab.
Natalizumab The risk or severity of adverse effects can be increased when Natalizumab is combined with Atoltivimab.
Palivizumab The risk or severity of adverse effects can be increased when Palivizumab is combined with Atoltivimab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Atoltivimab.
Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Atoltivimab.
Technetium Tc-99m arcitumomab The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Atoltivimab.
Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Atoltivimab.
Panitumumab The risk or severity of adverse effects can be increased when Panitumumab is combined with Atoltivimab.
Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Atoltivimab.
Galiximab The risk or severity of adverse effects can be increased when Galiximab is combined with Atoltivimab.
Pexelizumab The risk or severity of adverse effects can be increased when Pexelizumab is combined with Atoltivimab.
Afelimomab The risk or severity of adverse effects can be increased when Afelimomab is combined with Atoltivimab.
Epratuzumab The risk or severity of adverse effects can be increased when Epratuzumab is combined with Atoltivimab.
Bectumomab The risk or severity of adverse effects can be increased when Bectumomab is combined with Atoltivimab.
Oregovomab The risk or severity of adverse effects can be increased when Oregovomab is combined with Atoltivimab.
IGN311 The risk or severity of adverse effects can be increased when IGN311 is combined with Atoltivimab.
Adecatumumab The risk or severity of adverse effects can be increased when Adecatumumab is combined with Atoltivimab.
Labetuzumab The risk or severity of adverse effects can be increased when Labetuzumab is combined with Atoltivimab.
Matuzumab The risk or severity of adverse effects can be increased when Matuzumab is combined with Atoltivimab.
Fontolizumab The risk or severity of adverse effects can be increased when Fontolizumab is combined with Atoltivimab.
Bavituximab The risk or severity of adverse effects can be increased when Bavituximab is combined with Atoltivimab.
CR002 The risk or severity of adverse effects can be increased when CR002 is combined with Atoltivimab.
Rozrolimupab The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Atoltivimab.
Girentuximab The risk or severity of adverse effects can be increased when Girentuximab is combined with Atoltivimab.
Obiltoxaximab The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Atoltivimab.
XTL-001 The risk or severity of adverse effects can be increased when XTL-001 is combined with Atoltivimab.
NAV 1800 The risk or severity of adverse effects can be increased when NAV 1800 is combined with Atoltivimab.
Briakinumab The risk or severity of adverse effects can be increased when Briakinumab is combined with Atoltivimab.
Otelixizumab The risk or severity of adverse effects can be increased when Otelixizumab is combined with Atoltivimab.
AMG 108 The risk or severity of adverse effects can be increased when AMG 108 is combined with Atoltivimab.
Iratumumab The risk or severity of adverse effects can be increased when Iratumumab is combined with Atoltivimab.
Enokizumab The risk or severity of adverse effects can be increased when Enokizumab is combined with Atoltivimab.
Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Atoltivimab.
Farletuzumab The risk or severity of adverse effects can be increased when Farletuzumab is combined with Atoltivimab.
Veltuzumab The risk or severity of adverse effects can be increased when Veltuzumab is combined with Atoltivimab.
Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Atoltivimab.
Trastuzumab emtansine The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Atoltivimab.
PRO-542 The risk or severity of adverse effects can be increased when PRO-542 is combined with Atoltivimab.
TNX-901 The risk or severity of adverse effects can be increased when TNX-901 is combined with Atoltivimab.
Inotuzumab ozogamicin The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Atoltivimab.
RI 624 The risk or severity of adverse effects can be increased when RI 624 is combined with Atoltivimab.
Stamulumab The risk or severity of adverse effects can be increased when MYO-029 is combined with Atoltivimab.
CT-011 The risk or severity of adverse effects can be increased when CT-011 is combined with Atoltivimab.
Leronlimab The risk or severity of adverse effects can be increased when Leronlimab is combined with Atoltivimab.
Glembatumumab vedotin The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Atoltivimab.
Olaratumab The risk or severity of adverse effects can be increased when Olaratumab is combined with Atoltivimab.
IPH 2101 The risk or severity of adverse effects can be increased when IPH 2101 is combined with Atoltivimab.
TB-402 The risk or severity of adverse effects can be increased when TB-402 is combined with Atoltivimab.
Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Atoltivimab.
IMC-1C11 The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Atoltivimab.
Eldelumab The risk or severity of adverse effects can be increased when Eldelumab is combined with Atoltivimab.
Lumiliximab The risk or severity of adverse effects can be increased when Lumiliximab is combined with Atoltivimab.

Target Protein

Envelope glycoprotein GP

Referensi & Sumber

Synthesis reference: Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA: Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093/infdis/jiy285.
Artikel (PubMed)
  • PMID: 32080199
    Jacob ST, Crozier I, Fischer WA 2nd, Hewlett A, Kraft CS, Vega MA, Soka MJ, Wahl V, Griffiths A, Bollinger L, Kuhn JH: Ebola virus disease. Nat Rev Dis Primers. 2020 Feb 20;6(1):13. doi: 10.1038/s41572-020-0147-3.
  • PMID: 29860496
    Pascal KE, Dudgeon D, Trefry JC, Anantpadma M, Sakurai Y, Murin CD, Turner HL, Fairhurst J, Torres M, Rafique A, Yan Y, Badithe A, Yu K, Potocky T, Bixler SL, Chance TB, Pratt WD, Rossi FD, Shamblin JD, Wollen SE, Zelko JM, Carrion R Jr, Worwa G, Staples HM, Burakov D, Babb R, Chen G, Martin J, Huang TT, Erlandson K, Willis MS, Armstrong K, Dreier TM, Ward AB, Davey RA, Pitt MLM, Lipsich L, Mason P, Olson W, Stahl N, Kyratsous CA: Development of Clinical-Stage Human Monoclonal Antibodies That Treat Advanced Ebola Virus Disease in Nonhuman Primates. J Infect Dis. 2018 Nov 22;218(suppl_5):S612-S626. doi: 10.1093/infdis/jiy285.
  • PMID: 30333617
    Saphire EO, Schendel SL, Gunn BM, Milligan JC, Alter G: Antibody-mediated protection against Ebola virus. Nat Immunol. 2018 Nov;19(11):1169-1178. doi: 10.1038/s41590-018-0233-9. Epub 2018 Oct 17.

Contoh Produk & Brand

Produk: 2 • International brands: 0
Produk
  • Inmazeb
    Injection, solution • - • Intravenous • US • Approved
  • Inmazeb
    Injection, solution • - • Intravenous • US • Approved

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul